APA (7th ed.) Citation

M, G., A, F., G, S., D, A., V, B., I, L., . . . A, Z. (2026). From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching. Tumori, 112(1), 22. https://doi.org/10.1177/03008916251401048

Chicago Style (17th ed.) Citation

M, Gaudio, et al. "From Intravenous to Subcutaneous Pertuzumab/trastuzumab in Breast Cancer: Clinical and Pharmacoeconomic Drivers and Barriers to Switching." Tumori 112, no. 1 (2026): 22. https://doi.org/10.1177/03008916251401048.

MLA (9th ed.) Citation

M, Gaudio, et al. "From Intravenous to Subcutaneous Pertuzumab/trastuzumab in Breast Cancer: Clinical and Pharmacoeconomic Drivers and Barriers to Switching." Tumori, vol. 112, no. 1, 2026, p. 22, https://doi.org/10.1177/03008916251401048.